TERMINATION, ASSET TRANSFER AND TRANSITION AGREEMENT BETWEEN NAPO PHARMACEUTICALS, INC. AND GLENMARK PHARMACEUTICALS, LTD. DATED SEPTEMBER 22, 2017Termination, Asset Transfer and Transition Agreement • November 20th, 2017 • Jaguar Health, Inc. • Pharmaceutical preparations • New York
THIS TERMINATION, ASSET TRANSFER AND TRANSITION AGREEMENT (this “Agreement”) dated as of September 22, 2017 (“Transfer Date”), is entered into between Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation having its principal place of business at 201 Mission Street, Ste. 2375, San Francisco, California 94105 (“Napo”), and Glenmark Pharmaceuticals, Ltd., a company organized under the laws of the Republic of India having its principal place of business at Glenmark House, B D Sawant Marg, Chakala, Off Western Express Highway Andheri (E), Mumbai - 400099 (“Glenmark”).
